AbbVie 8-K: Rule 425 Filing Signals Potential Transaction

TL;DR

**AbbVie filed an 8-K for Rule 425, hinting at a major corporate event or offering.**

AI Summary

AbbVie Inc. filed an 8-K on February 12, 2024, primarily to satisfy filing obligations under Rule 425 of the Securities Act, indicating written communications related to a business combination or offering. This filing also lists various senior notes, including 1.375% due 2024, 1.250% due 2024, and 0.750% due 2027, all traded on the NYSE. For investors, this matters because it signals ongoing financial activities, potentially related to debt management or a significant transaction, which could impact future earnings or capital structure.

Why It Matters

This filing indicates AbbVie is engaged in activities that require specific disclosures under Rule 425, often related to mergers, acquisitions, or other significant corporate events, which could affect the company's strategic direction and financial health.

Risk Assessment

Risk Level: medium — The filing itself is administrative, but the underlying event requiring a Rule 425 disclosure could carry significant financial or strategic risks or opportunities for AbbVie.

Analyst Insight

Investors should monitor AbbVie's subsequent filings and press releases for details regarding the event that triggered the Rule 425 disclosure, as it could signal strategic shifts or capital structure changes.

Key Numbers

• $0.01 — Par Value (Par value of AbbVie's Common Stock)
• 1.375% — Senior Notes Interest Rate (Interest rate for Senior Notes due 2024)
• 1.250% — Senior Notes Interest Rate (Interest rate for Senior Notes due 2024 and 2031)
• 0.750% — Senior Notes Interest Rate (Interest rate for Senior Notes due 2027)
• 2.125% — Senior Notes Interest Rate (Interest rate for Senior Notes due 2028 and 2029)
• 2.625% — Senior Notes Interest Rate (Interest rate for Senior Notes due 2028)

Key Players & Entities

• AbbVie Inc. (company) — the registrant filing the 8-K
• February 12, 2024 (date) — date of earliest event reported and filing date
• Rule 425 (regulation) — Securities Act rule requiring specific written communications
• 1 North Waukegan Road, North Chicago, Illinois 60064-6400 (address) — AbbVie's principal executive offices
• 001-35565 (number) — AbbVie's Commission File Number

Forward-Looking Statements

• AbbVie will announce details of a significant corporate transaction or offering. (AbbVie Inc.) — medium confidence, target: 2024-05-12

FAQ

From the Filing

0001104659-24-013692.txt : 20240212 0001104659-24-013692.hdr.sgml : 20240212 20240212074924 ACCESSION NUMBER: 0001104659-24-013692 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240212 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240212 DATE AS OF CHANGE: 20240212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 24617405 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 tm245657d1_8k.htm FORM 8-K false 0001551152 Common Stock, $0.01 Par Value ABBV 0001551152 2024-02-12 2024-02-12 0001551152 us-gaap:CommonStockMember exch:XNYS 2024-02-12 2024-02-12 0001551152 exch:XCHI us-gaap:CommonStockMember 2024-02-12 2024-02-12 0001551152 abbv:SeniorNotes1.375Percentdue2024Member exch:XNYS 2024-02-12 2024-02-12 0001551152 abbv:SeniorNotes1.250Percentdue2024Member exch:XNYS 2024-02-12 2024-02-12 0001551152 abbv:SeniorNotes0.750Percentdue2027Member exch:XNYS 2024-02-12 2024-02-12 0001551152 abbv:SeniorNotes2.125Percentdue2028Member exch:XNYS 2024-02-12 2024-02-12 0001551152 abbv:SeniorNotes2.625Percentdue2028Member exch:XNYS 2024-02-12 2024-02-12 0001551152 abbv:SeniorNotes2.125Percentdue2029Member exch:XNYS 2024-02-12 2024-02-12 0001551152 abbv:SeniorNotes1.250Percentdue2031Member exch:XNYS 2024-02-12 2024-02-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549     FORM 8-K       CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 12, 2024   ABBVIE INC. (Exact name of registrant as specified in its charter)   Delaware   001-35565   32-0375147 (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (I.R.S. Employer Identification Number)         1 North Waukegan Road North Chicago , Illinois 60064-6400 (Address of principal executive offices)(Zip Code)    Registrant’s telephone number, including area code: ( 847 ) 932-7900   Former name or former address, if changed since last report: Not Applicable   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange Chicago Stock Exchange 1.375% Senior Notes due 2024   ABBV24   New York Stock Exchange 1.250% Senior Notes due 2024   ABBV24B   New York Stock Exchange 0.750% Senior Notes due 2027   ABBV27   New York Stock Exchange 2.125% Senior Notes due 2028   ABBV28   New York Stock Exchange 2.625% Senior Notes due 2028   ABBV28B   New York Stock Exchange 2.125% Senior Notes due 2029